FDA approves Jazz Pharmaceutical’s NDA for solriamfetol in OSA patients
Jazz Pharmaceuticals affirmed that the U.S Food and Drug Administration has conceded for filing with standard review the company's New Drug Application requesting marketing approval for…
Read More...
Read More...